同时对CD73/EGFR轴的阻塞抑制了瘤生长
Keivan Ardeshiri1, Hadi Hassannia2,3, Ghasem Ghalamfarsa4
1Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.
IUBMB life
|January 2, 2025
概括
使用纳米载体同时向CD73和表皮生长因子受体 (EGFR),有效降低乳腺癌细胞死亡和瘤生长. 这种结合的方法显示了作为一种新的癌症免疫治疗策略的希望.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 纳米技术 纳米技术
背景情况:
- 瘤微环境因素显著影响癌症的进展,免疫逃避和治疗耐药性.
- 合作因素的联合向提供了比单剂疗法更高的疗效.
- CD73和EGFR是瘤生长的关键因素,表现出表达和功能的相互刺激.
研究的目的:
- 使用先前特征化的纳米载体,研究抗CD73和抗EGFRsiRNAs同时递送的疗效.
- 评估沉默CD73/EGFR轴对小鼠乳腺癌4T1细胞和瘤生长的影响.
主要方法:
- 利用纳米载体对siRNA针对CD73和EGFR进行向传递.
- 评估了siRNA传递对4T1细胞活力,迁移和增殖的影响.
- 在in ovo瘤生长模型中评估了治疗效果.
主要成果:
- 抑制CD73和EGFR显著诱导癌细胞死亡.
- CD73/EGFR轴的下调抑制了癌细胞的迁移和增殖.
- 结合治疗策略抑制了in ovo模型中的瘤生长.
结论:
- 同时向CD73和EGFR是对抗乳腺癌的有效策略.
- 这种方法需要进一步研究,作为一种新的免疫治疗策略.
关键词:
4T1 一个人的生活CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73 CD73欧洲农业基金会 (EGFR) 是一个.乳腺癌 乳腺癌 乳腺癌癌症治疗疗法 癌症治疗纳米颗粒是一种纳米粒子.更多相关视频
相关概念视频
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Inhibition of Cdk Activity
4.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.5K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy
394
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
394
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Interactions Between Signaling Pathways
6.1K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.1K


